Background
==========

Postoperative pain is one of the most untreated medical problems, and an annoying subjective sensation for patients, especially in children. A variety of methods have evolved for supposing postoperative pain relief in pediatric patients to provide a better quality of sleep and prolong the duration of sedation \[[@b1-medscimonit-25-165]\]. Caudal epidural block is normally a safe technique performed in pediatric anesthesia. The main disadvantage of a caudal block is the shortest duration of analgesia after a single injection, it works for only for 4 to 8 hours \[[@b2-medscimonit-25-165],[@b3-medscimonit-25-165]\], even with the use of bupivacaine (BU), levobupivacaine, or ropivacaine. Therefore, various adjuvants, such as morphine \[[@b4-medscimonit-25-165]\], ketamine \[[@b5-medscimonit-25-165],[@b6-medscimonit-25-165]\], ephedrine \[[@b6-medscimonit-25-165]\], clonidine and neostigmine \[[@b7-medscimonit-25-165],[@b8-medscimonit-25-165]\], opioids \[[@b9-medscimonit-25-165]--[@b11-medscimonit-25-165]\], and dexmedetomidine (DEX) \[[@b12-medscimonit-25-165]\] have been investigated to caudal local anesthetics.

DEX is a powerful and highly selective α~2~ adrenergic agonist that has been defined as a safe and effective additive in many anesthetic applications \[[@b13-medscimonit-25-165]\], and is being used increasingly in children \[[@b14-medscimonit-25-165],[@b15-medscimonit-25-165]\]. Substantial studies have shown that DEX added to BU in caudal epidural block can prolong sedation time and reduce side effects, but this conclusion is still controversial \[[@b16-medscimonit-25-165],[@b17-medscimonit-25-165]\]. However, there are still some concerns regarding its safety \[[@b18-medscimonit-25-165]\]. The purpose of this meta-analysis was to assess the efficacy and safety of DEX in addition to caudal analgesia in children undergoing lower abdominal, perineal, and lower limb surgeries, and to help provide a reliable basis for the selection of surgical anesthesia in children.

Material and Methods
====================

Search strategies and study selection
-------------------------------------

This meta-analysis was reported in accordance with the PRISMA-P Statement \[[@b19-medscimonit-25-165]\]. Published studies were identified using the databases of PubMed, Embase, Cochrane Library, and Web of Science from their inception until October 2017. We used the following combined keywords and MeSH terms: 'dexmedetomidine' AND 'Bupivacaine' AND 'children' OR 'Pediatric' OR 'child' OR 'childhood' OR 'Toddler' OR 'Adolescence' OR 'Infancy'. We also detected further studies by scanning the reference list of retrieved researches.

A study was considered eligible for our meta-analysis if it included the following criteria: 1) for patients, only general anesthesia patients, American Society of Anesthesiologists (ASA) I--II, aged less than 12 year undergoing lower abdominal, perineal, and lower limb surgeries, we applied no type of surgery restrictions; 2) for study types, only RCTs with a concrete randomized method and double-blind clinical trials; 3) for interventions, only if BU was involved in caudal epidural block, the control group received BU (or levobupivacaine) alone and the comparison group received BU (or levobupivacaine) + DEX; 4) for outcomes, the primary efficacy endpoints was duration of analgesia (the time of first postoperative rescue analgesics required), secondary efficacy endpoints was incidence of patients to first analgesics administration at 6 hours,12 hours and 24 hours; the primary safety endpoints included side effect of nausea and vomiting. If any of these principles were not met, the study was excluded.

Data extraction and quality assessment
--------------------------------------

Two investigators independently reviewed publications for eligibility, with disagreements resolved by a third agent. Studies that met inclusion criteria were selected for further analysis. We extracted the following data from each selected study: total number of participants, age, surgery style, blocking methods, and ASA. The Cochrane Collaboration tool was used to estimate the risk of bias in the inclusion studies, which classifies the risk for bias as low, unclear, or high \[[@b20-medscimonit-25-165]\].

Statistical analysis
--------------------

The primary outcomes of our analysis were the duration of analgesia, which was a continuous variable, and data was pooled together in the form of standardized mean difference (SMD) with 95% confidence interval (CI). When SMD \>0 and *P*\<0.05, the anesthetic effect of DEX + BU group (DEX add to BU in general anesthesia patient) was better than that of BU group (only BU). For secondary outcomes and side effects, in the case of qualitative data, we used risk ratio (RR) with 95% CI. When RR \>1 and *P*\<0.05, the side effects of DEX + BU group were considered to be higher than that of BU group.

The Cochran Q statistic with chi-square test and the Higgins *I*^2^ test were used to determine the heterogeneity between-study variability. The Cochran's Q Test *P*\<0.05 or *I*^2^\>50% or more indicate significant heterogeneity, and the data will be analyzed through the random effect model. On the contrary, the fixed effect model will be chosen. Influence analysis was also conducted to regulate whether an individual study affected the aggregate result or not. We assessed publication bias by funnel plots and Egger's test. Statistical analyses were performed using Stata 12.0 and Review Manager 5.3.

Results
=======

The literature search found 198 documents, of which 159 studies were excluded after our review of titles and abstracts. The full text of 39 remaining citations was screened, and finally 10 articles (12 studies) including 691 patients were included \[[@b1-medscimonit-25-165],[@b16-medscimonit-25-165],[@b17-medscimonit-25-165],[@b21-medscimonit-25-165]--[@b27-medscimonit-25-165]\]. The flow chart of the meta-analysis is presented in [Figure 1](#f1-medscimonit-25-165){ref-type="fig"}. The characteristics of the included studies are listed in [Table 1](#t1-medscimonit-25-165){ref-type="table"}, and the methodological quality of the evaluation results are presented in [Figure 2](#f2-medscimonit-25-165){ref-type="fig"}. In the DEX + BU trials, 2 different doses of DEX (1 μg/kg and 2 μg/kg) were investigated. Therefore, we did a dose grouping in order to reduce heterogeneity at the time of the merger.

Primary outcomes: duration of analgesia
---------------------------------------

The merged effect analysis showed that combining DEX + BU can significantly extend the duration of analgesia with a mean time of 13.83 hours in the DEX + BU group compared to 5.81 hours in the BU group (SMD=3.19, 95% CI: 2.16--4.22, *I*^2^=96.1%). DEX at 1 μg/kg and 2 μg/kg was associated with extending the time to first supplemental analgesics (SMD=3.76, 95% CI: 2.16--5.37, *I*^2^=97.4% and SMD=2.30, 95% CI: 1.73--2.87, *I*^2^=64.7% respectively), and there were no significantly differences with 1 μg/kg DEX versus 2 μg/kg DEX (SMD=0.43, 95% CI: −0.09--0.94, *I*^2^=48.4%) ([Figure 3](#f3-medscimonit-25-165){ref-type="fig"}).

Secondary outcomes: number of patients who received rescue analgesia
--------------------------------------------------------------------

Secondary efficacy endpoints were the incidence of patients to first analgesics administration at 6 hours, 12 hours and 24 hours. From the meta-analysis, DEX + BU was significantly more effective than BU alone (6 hours: RR=0.09, 95% CI: 0.05--0.17, *I*^2^=33.9%; 12 hours: RR=0.50, 95% CI: 0.32--0.79, *I*^2^=81.4%; 24 hours: RR=0.66, 95% CI: 0.51--0.85, *I*^2^=85.9%). The results of subgroup analysis are shown in [Table 2](#t2-medscimonit-25-165){ref-type="table"}.

Adverse events: the incidence of nausea and vomiting
----------------------------------------------------

Nausea and vomiting are common side effects of sacral anesthesia in children and are used to evaluate safety. The incidence of nausea and vomiting was described in 7 studies, the doses of DEX were 2 μg/kg and 1 μg/kg, respectively. The pooled results of the adverse events between the BU only group and the DEX + BU group were not statistically significant (*P*\>0.05), (RR=0.96, 95% CI: 0.58--1.58). All the observed *I*^2^ were 0% ([Figure 4](#f4-medscimonit-25-165){ref-type="fig"}).

Sensitivity analysis for the primary outcomes
---------------------------------------------

We did a sensitivity analysis for duration of analgesia. When these trials were removed individually, significant differences were still found in duration of analgesia ([Figure 5](#f5-medscimonit-25-165){ref-type="fig"}), suggesting that the pooled data results are robust.

Publication bias for the primary outcomes
-----------------------------------------

Funnel plot and Egger's publication bias plot revealed strong asymmetry ([Figure 6](#f6-medscimonit-25-165){ref-type="fig"}), suggesting potential publications bias.

Discussion
==========

There were several chief observations from this meta-analysis. The use of DEX combined with BU in caudal epidural block had a statistically significant effect on the duration of analgesia compared to using BU alone. The DEX + BU group had a longer time before patients needed first supplemental analgesic and fewer patients who received rescue analgesia, compared to the BU group, and did not show a difference in the incidence of nausea and vomiting. There were no significantly differences with DEX at 1 μg/kg versus 2 μg/kg. However, there was significant heterogeneity among the studies; therefore, the quality of the results was low.

Our meta-analysis results agree with earlier studies concerning the effectiveness of DEX in prolonging the duration of postoperative analgesia \[[@b28-medscimonit-25-165],[@b29-medscimonit-25-165]\], and reducing the number of patients who needed rescue analgesia. Attributable to the possible influence of data heterogeneity, further studies were required to determine the analgesics effect of different concentrations of DEX used in caudal block. We conducted an additional meta-analysis on defined anesthetic drugs BU or levobupivacaine, and conducted a subgroup analysis of the dosage of DEX. This study found that 1 μg/kg or 2 μg/kg DEX was associated with extending the time to first supplemental analgesics. Two other studies compared different doses of DEX (1 μg/kg and 2 μg/kg) and the results were not identical. Al-Zaben et al. \[[@b21-medscimonit-25-165]\] concluded a 1 μg/kg dose of caudal DEX achieved equivalent extension of postoperative analgesia to 2 μg/kg dose, with shorter duration of postoperative sedation and lower incidence of other side effects. Meenakshi et al. \[[@b17-medscimonit-25-165]\] found that 1 μg/kg DEX was as effective as 2 μg/kg DEX and had a better safety profile.

Although we have done a dose-grouping on DEX (with 1 μg/kg or 2 μg/kg) to reduce the heterogeneity, the results for time to first supplemental analgesics of DEX with 1 μg/kg showed significant heterogeneity (*I*^2^=97.4%). While the exact cause could not be detected, we doubt that the differences in the age range of children among the studies was one of the reasons. In the articles, the age range of the participating children was heterogeneous. The age ranges in the Meenakshi et al. study and the Goyal et al. study was different from the other studies (6 months to 8 years of age versus 2 years to 10 years of age). We conducted subgroup analysis based on age range and found that as the heterogeneity decreased, so did the difference in the age range, which might be one of the sources of the heterogeneity.

We doubted that another reason for the heterogeneity could be the indications for different operation. The pain response in extreme surgery and abdominal surgery will be different from other indications. The operation criteria used in the Elfawal et al. study was lower limb surgeries, whereas the other studies used lower abdominal surgeries. We also doubted that the use of levobupivacaine or BU made a difference in terms of motor response generation and duration of drug action. Elfawal et al. used levobupivacaine; in our influence analysis, when this trial was removed, no significant reduction in heterogeneity was found.

Furthermore, α~2~-adrenergic agonists have been studied for effects of hypotension and tachycardia on hemodynamics and reduced incidence of postoperative nausea \[[@b30-medscimonit-25-165]\]. The introduction of DEX, one of the highly selective α~2~-adrenergic agonists, has further broadened the use of α~2~-adrenergic agonists in recent years \[[@b31-medscimonit-25-165],[@b32-medscimonit-25-165]\]. In the 10 studies included in our meta-analysis, no serious side effects were described. Even though the incidence of nausea and vomiting between the BU group and the DEX + BU group were not statistically significant, we did find that as the dosage of DEX increased, the incidence of nausea and vomiting increased. However, 2 articles reported that a 2 μg/kg dose caudal DEX compared to a 1 μg/kg dose of caudal DEX had a higher incidence of other side effects.

There were several limitations to our study. Although we used dose-grouping for DEX to reduce heterogeneity, the heterogeneity in some studies was still large. Furthermore, the influence of publication bias cannot be ignored; the methodological quality of our results representing reporting bias was unclear for the included studies, and the Funnel plot and Egger's publication bias plot revealed strong asymmetry. The different methods used in studies for postoperative pain assessment and the triggers used for rescue analgesics might have introduced bias into some outcomes, especially for the duration of analgesia. Thus, some results of our research might be influenced by bias. The concentration and dose of BU administered caudally varied between the studies and this might have influenced the postoperative analgesic effect.

Conclusions
===========

DEX seems to be a promising adjuvant to BU to increase the duration of caudal analgesia without an increase in side effects in a pediatric patients. However, the results of our meta-analysis might have been influenced by clinical heterogeneity and insufficient data. More large-scale, multicenter, double-blinded RCTs are required to confirm our results.
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###### 

Characteristics of the included studies.

  First author   Year   Surgery style                                                                                   N     Age        ASA     Inhaled anesthesia                                           Blocking methods   Anesthesia position          Anesthesia needle type      Control group                                         Case group                                                          Pain trigger
  -------------- ------ ----------------------------------------------------------------------------------------------- ----- ---------- ------- ------------------------------------------------------------ ------------------ ---------------------------- --------------------------- ----------------------------------------------------- ------------------------------------------------------------------- -----------------
  Lei            2014   Infraumbilical surgeries                                                                        80    1--6 y     I--II   8% sevoflurane + 8 L/min oxygen                              Caudal analgesia   Lateral decubitus position   23 G needle                 1 mL/kg levobupivacaine 0.25%                         Levobupivacaine 0.25% + 2 μg/kg DEX                                 FLACC \>3
  Meenakshi      2016   Paediatric infraumbilical surgeries                                                             90    6 m--8 y   I--II   Oxygen and nitrous oxide in 1: 1 ratio and halothane 1--3%   Caudal analgesia   Lateral decubitus position   \-\--                       1 mL/kg bupivacaine 0.25%                             1 mL/kg of 0.25% bupivacaine + 1 or 2 μg/kg DEX                     FLACC \>4
  Elfawal        2016   Lower limb surgeries (lower extremity lengthening, correction of lower extremity deformities)   60    1--7 y     I--II   Sevoflurane in oxygen/air (FiO2 50%)                         Caudal analgesia   Lateral decubitus position   23 G needle                 0.75 mL/kg levobupivacaine 0.25% diluted in 0.9% NS   0.75 mL/kg levobupivacaine + 1 μg/kg DEX                            FLACC \>4
  Goyal          2016   Elective infraumbilical surgeries                                                               100   2--10 y    I--II   Sevoflurane                                                  Caudal analgesia   Left lateral position        \-\--                       1 mL/kg bupivacaine 0.25%                             1 mL/kg bupivacaine 0.25% + 1 μg/kg DEX                             \-\--
  El-Hennawy     2009   Lower abdominal surgeries                                                                       40    6 m--6 y   I--II   Sevoflurane delivered in oxygen                              Caudal analgesia   Lateral decubitus position   23 G needle                 1 mL/kg bupivacaine 0.25%                             1 mL/kg bupivacaine 0.25% + 2 μg/kg DEX                             FLACC \>4
  Saadawy        2008   Unilateral inguinal hernia repair/orchidopexy                                                   60    1--6 y     I--II   0.5--2% sevoflurane and 70% nitrous oxide in oxygen          Caudal analgesia   Lateral position             23-G short-beveled needle   1 mL/kg bupivacaine 2.5 mg/mL                         bupivacaine 2.5 mg/mL, 1 mL/kg + 1 μg/kg DEX                        OPS ≥4
  Al-Zaben       2015   Infra-umbilical surgery                                                                         91    1--6 y     I       Sevoflurane                                                  Caudal analgesia   Lateral decubitus position   23-G short-beveled needle   1 mL/kg bupivacaine 0.25%                             bupivacaine 0.25% at a dose of 0.8 mL/kg + 1 μg/kg or 2 μg/kg DEX   OPS ≥4
  Al-Zaben       2016   Elective lower abdominal and perineal surgeries                                                 50    1--6 y     I       8% sevoflurane in 100% oxygen via facemask                   Caudal analgesia   Left lateral position        22-G needle                 1 mL/kg caudal 0.25% bupivacaine                      1 mL/kg caudal 0.25% bupivacaine + 1 μg/kg DEX                      OPS ≥4
  Xiang          2012   Unilateral inguinal hernia repair/orchidopexy                                                   60    1--6 y     I       \-\--                                                        Caudal analgesia   Left lateral position        22-G needle                 1 mL/kg bupivacaine 0.25%                             1 mL/kg bupivacaine 0.25% + 1 μg/kg DEX                             CHIPPS \>3
  Kannojia       2017   Urogenital surgery                                                                              60    2--7 y     I--II   Sevoflurane                                                  Caudal analgesia   Lateral decubitus position   23 G shot needle            0.5 mL/kg bupivacaine 0.25%                           0.5 mL/kg bupivacaine 0.25% + 1 μg/kg DEX                           CHEOP scale \>6

m -- month; y -- year; \-\-- -- null; ASA -- American Society of Anesthesiology; DEX -- dexmedetomidine; CHIPPS -- Children and Infants Postoperative Pain Scale; FLACC -- face, legs, activity, cry, consolability; OPS -- Objective Pain Score; CHEOPS -- Children's Hospital of Eastern Ontario Pain Scale.

###### 

Number of patients requiring a rescue analgesia.

  Time to first analgesic administration   Does of DEX            RR (95% CI)            P of RR   *I*^2^    *P*
  ---------------------------------------- ---------------------- ---------------------- --------- --------- ---------
  6 hour                                   Overall                0.093 (0.051, 0.170)   \<0.001   33.90%    0.169
  1 μg/kg                                  0.096 (0.049, 0.191)   \<0.001                44.2%     0.128     
  2 μg/kg                                  0.085 (0.025, 0.291)   \<0.001                45.8%     0.175     
  12 hour                                  Overall                0.502 (0.321, 0.786)   0.003     81.4%     \<0.001
  1 μg/kg                                  0.326 (0.123, 0.869)   0.025                  91.3%     \<0.001   
  2 μg/kg                                  0.559 (0.432, 0.723)   \<0.001                0.0%      0.622     
  24 hour                                  Overall                0.657 (0.507, 0.853)   0.002     85.9%     \<0.001
  1 μg/kg                                  0.642 (0.497, 0.831)   0.001                  63.8%     0.04      
  2 μg/kg                                  0.695 (0.424, 1.138)   0.148                  92.6%     \<0.001   
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